Precision BioSciences - DTIL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.25
  • Forecasted Upside: 768.79 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.41
▲ +0.11 (8.46%)

This chart shows the closing price for DTIL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Precision BioSciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DTIL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DTIL

Analyst Price Target is $12.25
▲ +768.79% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Precision BioSciences in the last 3 months. The average price target is $12.25, with a high forecast of $20.00 and a low forecast of $2.00. The average price target represents a 768.79% upside from the last price of $1.41.

This chart shows the closing price for DTIL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Precision BioSciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/5/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/3/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/9/2022The Goldman Sachs GroupLower TargetNeutral$3.00 ➝ $2.00Low
6/23/2022HC WainwrightReiterated RatingBuy$20.00Low
6/16/2022BMO Capital MarketsInitiated CoverageOutperform$7.00Medium
6/9/2022HC WainwrightReiterated RatingBuy$20.00High
6/9/2022William BlairDowngradeOutperform ➝ Market PerformHigh
3/16/2022The Goldman Sachs GroupLower TargetNeutral$12.00 ➝ $5.00High
12/12/2021BTIG ResearchReiterated RatingBuy ➝ Buy$16.00 ➝ $20.00High
10/21/2021HC WainwrightReiterated RatingBuy$21.00Low
9/10/2021Stifel NicolausBoost TargetBuy$23.00 ➝ $26.00Medium
3/18/2021JonestradingReiterated RatingBuy$27.00High
2/24/2021JonestradingInitiated CoverageBuy$27.00Low
1/29/2021JPMorgan Chase & Co.Boost Target$10.00 ➝ $14.00Medium
12/15/2020HC WainwrightReiterated RatingBuyLow
12/7/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$18.00 ➝ $10.00High
11/23/2020Stifel NicolausBoost Target$21.00 ➝ $22.00High
8/17/2020BarclaysReiterated RatingBuy$18.00Medium
6/12/2020HC WainwrightReiterated RatingBuy$19.00High
6/8/2020William BlairReiterated RatingBuyHigh
4/8/2020HC WainwrightReiterated RatingBuy$19.00High
4/2/2020The Goldman Sachs GroupDowngradeBuy ➝ NeutralHigh
3/11/2020HC WainwrightLower TargetBuy$21.00 ➝ $19.00High
3/4/2020Stifel NicolausInitiated CoverageBuy$21.00Low
2/25/2020William BlairReiterated RatingOutperformHigh
1/21/2020HC WainwrightReiterated RatingBuy$21.00Medium
11/13/2019HC WainwrightReiterated RatingBuy$21.00High
10/21/2019HC WainwrightSet TargetBuy$21.00High
8/9/2019BTIG ResearchInitiated CoverageBuy ➝ Buy$22.00High
7/16/2019HC WainwrightInitiated CoverageBuy ➝ Buy$21.00Medium
4/22/2019Jefferies Financial GroupInitiated CoverageBuy ➝ BuyHigh
4/22/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$23.00High
4/22/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$24.00High
4/22/2019BarclaysInitiated CoverageOverweight ➝ Overweight$24.00High
(Data available from 10/3/2017 forward)

News Sentiment Rating

0.69 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/7/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/6/2022
  • 3 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/6/2022
  • 6 very positive mentions
  • 24 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/5/2022
  • 7 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
7/5/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
8/4/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/3/2022
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/3/2022

Current Sentiment

  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Precision BioSciences logo
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $1.41
Low: $1.33
High: $1.44

50 Day Range

MA: $1.59
Low: $1.22
High: $2.06

52 Week Range

Now: $1.41
Low: $1.11
High: $11.61

Volume

35,161 shs

Average Volume

1,604,255 shs

Market Capitalization

$156.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51

Frequently Asked Questions

What sell-side analysts currently cover shares of Precision BioSciences?

The following Wall Street research analysts have issued stock ratings on Precision BioSciences in the last twelve months: BMO Capital Markets, BTIG Research, HC Wainwright, The Goldman Sachs Group, Inc., TheStreet, and William Blair.
View the latest analyst ratings for DTIL.

What is the current price target for Precision BioSciences?

4 Wall Street analysts have set twelve-month price targets for Precision BioSciences in the last year. Their average twelve-month price target is $12.25, suggesting a possible upside of 768.8%. BTIG Research has the highest price target set, predicting DTIL will reach $20.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $2.00 for Precision BioSciences in the next year.
View the latest price targets for DTIL.

What is the current consensus analyst rating for Precision BioSciences?

Precision BioSciences currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DTIL will outperform the market and that investors should add to their positions of Precision BioSciences.
View the latest ratings for DTIL.

What other companies compete with Precision BioSciences?

How do I contact Precision BioSciences' investor relations team?

Precision BioSciences' physical mailing address is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. The company's listed phone number is (919) 314-5512 and its investor relations email address is [email protected] The official website for Precision BioSciences is www.precisionbiosciences.com. Learn More about contacing Precision BioSciences investor relations.